•   
  •   

Australia Australia needs 'entire rethink' of vaccine strategy: epidemiologist

03:40  11 april  2021
03:40  11 april  2021 Source:   9news.com.au

Why Hong Kongers Are Slow to Get a Vaccine

  Why Hong Kongers Are Slow to Get a Vaccine As a result of mass alienation among the population, the city views its leadership with intense suspicion.Now, however, the city is having trouble getting the public to take part in its vaccination drive, an effort hampered in large part by deep suspicion of the government and a historically unpopular leader who has struggled mightily to convince the public of the benefits of getting inoculated. An abundance of vaccines, officials are discovering, means very little when trust is in such short supply.

Logistical concerns around administering the Pfizer vaccine are likely to further delay Australia's already tardy vaccination progress. © Getty Logistical concerns around administering the Pfizer vaccine are likely to further delay Australia's already tardy vaccination progress.

The Federal Government needs to "entirely rethink" its coronavirus vaccination strategy after new health advice recommending that what had been intended as Australia's primary vaccine not be given to those under 50, according to a leading Australian epidemiologist.

"The vaccine program frankly was already pretty much in disarray," Professor Nancy Baxter told the Weekend Today show this morning.

"Now that we have to wait for a large part of the population for the Pfizer to come, they will have to rethink the program entirely."

Australian man, 44, hospitalised with blood costs after Covid vaccine

  Australian man, 44, hospitalised with blood costs after Covid vaccine The 44-year-old got the jab on March 22 and later presented to a Melbourne hospital suffering fever and abdominal pain, and was found to have blood clots in his abdomen.The 44-year-old got the jab on March 22 and later presented to Box Hill Hospital in Melbourne suffering fever and abdominal pain.

It comes after the Australian Technical Advisory Group on Immunisation (ATAGI) issued updated advice recommending that the AstraZeneca jab be reserved for those over the age of 50, due to a rare but serious side effect of a blood clotting disorder.

Professor Baxter said Australians under 50 could still elect to receive the AstraZeneca vaccine if they choose, noting the risk remained remote.

The AstraZeneca vaccine has much less stringent storage criteria compared to the Pfizer shot, presenting further logistical challenges for the government. © Nine The AstraZeneca vaccine has much less stringent storage criteria compared to the Pfizer shot, presenting further logistical challenges for the government.

"It's uncommon - about 1 in 100,000 to one in 200,000 people - meaning that 99,999 people who get the AstraZeneca vaccine do not have a problem," she said.

Around one-quarter of those who do develop the blood clotting reaction will die.

Urgent AstraZeneca Covid vaccine probe lauched after man hospitalised

  Urgent AstraZeneca Covid vaccine probe lauched after man hospitalised Australia's medicines regulator has begun an urgent investigation into the AstraZeneca Covid vaccine after a man was hositalised with a rare blood clotting condition. The Therapeutic Goods ­Administration held talks with British regulators overnight probing whether the 44-year-old's low blood platelets and 22 other similar cases in the UK are linked to the vaccine.Discussions will continue on Saturday between the Australian Health Protection Principal Committee and the Australian Technical Advisory Group on Immunisation.

Professor Baxter noted that this was still lower than the risk profile for many other drugs which continue to be used in Australia.

"When we give any medication, there's always some risks of side-effects. That's accepted because of the benefit of the medication," she said.


Video: Specific groups could be ‘managed differently’ in relation to AstraZeneca vaccine (Sky News Australia)

"If you got penicillin for an infection, there's ten times the risk there would be a serious drug reaction with that drug (compared to the AstraZeneca vaccine)."

Professor Baxter said the age cut-off was in part based on a weighing up of the risks of the vaccine versus the risks of contracting coronavirus.

"Older people are at more risk of COVID-19, so the risk-benefit equation balances out better for them," she said.

"Also, there is some data that indicates age is a risk factor, so younger people are more likely to get it (blood clots) than older people."

Decision about AstraZeneca's use in Australia to be make this week

  Decision about AstraZeneca's use in Australia to be make this week An urgent investigation was launched into the potential side effects of the Covid-19 vaccine after a Melbourne man who received the jab was hospitalised with a rare blood clotting condition. Experts have been holding talks with European regulators to determine whether the 44-year-old's low blood platelets and 22 other similar cases in the UK are linked to the vaccine. The Australian Technical Advisory Group on Immunisation (ATAGI) will convene on Wednesday to weigh up the risks and benefits of AstraZeneca jabs once further information is provided from international discussions.

It's expected that more data will be uncovered over the coming months.

The Federal Government has already responded to the ATAGI recommendation by contracting a further 20 million doses of the Pfizer shot in addition to 20 million already secured - enough to vaccinate the bulk of the adult Australian population - but those additional doses won't arrive in Australia until at least October.

Professor Baxter, who is the head of the Melbourne School of Population and Global Health, said Australia should already have enough Pfizer doses to progress through Phase 1B of its vaccine rollout.

This includes vaccinating all Australians over the age of 70 and Indigenous Australians over 55 - all of whom can still receive AstraZeneca under current health advice - but also many younger Australians, including healthcare workers, emergency responders and those with underlying medical conditions that make them vulnerable.

However, logistical concerns around administering the Pfizer vaccine are likely to further delay Australia's already tardy vaccination progress.

Here's why the AstraZeneca COVID vaccine is recommended for over 50s but not other Australians

  Here's why the AstraZeneca COVID vaccine is recommended for over 50s but not other Australians But if you're wondering what Australia's vaccine changes mean for you, or whether it's still safe to take the AstraZeneca vaccine, here's what the expert advice is saying.With the government accepting advice that the small risk of blood clots associated with the AstraZeneca vaccine means it should not be given to people under 50, its plan to vaccinate Australians against the virus is in disarray.

More ultra-low temperature freezers will likely need to be secured and getting the vaccine to more remote locations could prove problematic.

Australia's third vaccine option, Novavax, has been contracted for 51 million doses but is unlikely to be approved for use in Australia for several months as it is still undergoing phase three clinical trials in the United Kingdom.

"We have to reboot - they really need to rethink the program," Professor Baxter said.

"Once we get enough Pfizer to be vaccinating a large number of people, we need to look at how we approach it.

"We need to do it faster than we were hoping before, if we're hoping to get everyone vaccinated by the end of the year."

It's a goal that now appears unlikely, with Prime Minister Scott Morrison refusing to outline a revised timeline for the vaccination program at his National Cabinet update on Friday.

Is it time for Australia to dump its vaccination strategy and start making its own vaccine? .
The vaccine rollout is done for and there's no real plan to get it back on track. Is it time to roll up our sleeves and get the job done ourselves?Today: in the face of new COVID-19 variants and supply shortages, is it time to stop relying on foreign companies and start manufacturing our own vaccines in earnest?

usr: 1
This is interesting!